Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT06321081 Recruiting - Clinical trials for Metastatic Colorectal Cancer

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients have been treated in front lines with irinotecan and cetuximab and had a clinical benefit (complete or partial response) from both of them, no matter whether they had treated by any PD-1 inhibitor before.

NCT ID: NCT06313268 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Safety of Effivia®, a Bevacizumab Biosimilar

Start date: April 21, 2022
Phase:
Study type: Observational [Patient Registry]

This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.

NCT ID: NCT06296056 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the safety, immune response, and potential efficacy of combined immune cell therapy in patients with stage 4 colorectal cancer who have failed standard treatment and have unresectable lesions or metastatic lesions.

NCT ID: NCT06290856 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy

Start date: January 15, 2024
Phase:
Study type: Observational

Circulating tumor DNA assays are becoming relevant for routine diagnostics, but many related aspects are yet unresolved. With this project, the investigators aim to develop pragmatic molecular diagnostic pathways of liquid biopsies relevant in advanced gastrointestinal malignancies with focus on clinical utility and sensible use of resources. They want to evaluate the ctDNA assays on a fully automated "low-cost" multiplex platform which is already implemented in routine molecular diagnostics of solid biopsies. The project will evaluate to what extent these ctDNA assays are relevant for clinical decision-making.

NCT ID: NCT06252649 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

CodeBreaK 301
Start date: April 30, 2024
Phase: Phase 3
Study type: Interventional

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

NCT ID: NCT06245356 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

TRIFLUOX-DP
Start date: June 20, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. The main questions it aims to answer are: - Is this alternative chemotherapy option a better option in term of safety for this type of patients? - Does the combination of treatments improves the overall safety? - Does the combination of treatments improves the progression-free survival, overall survival, objective response rate and disease control rate? - Does the combination of treatment have an effect on quality of life? Participants will: - Receive the trifluridine/tipiracil with oxaliplatin every 14 days, associated with: - Panitumumab or bevacizumab for colorectal adenocarcinomas - Nivolumab or trastuzumab for gastroesophageal adenocarcinomas. - Have a CT-Scan every 2 months until disease progression - Complete Health-related quality of life questionnaire every 2 months for a maximum of 6 months - Participate to the optional translational research: Blood samples fo DPYD genotyping and pharmacokinetic analysis

NCT ID: NCT06243393 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Sacituzumab Govitecan in Metastatic Colorectal Cancer

TROPHIT1
Start date: April 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase: II/III, open-label, multicenter (at least four centers in Germany) study of Sacituzumab Govitecan (SG) in metastatic colorectal cancer patients who are refractory to at least two lines of standard of care chemotherapy and not eligible for local therapy. There is no upper limit in the previous therapy lines. Patients must have documented progression or intolerability to combination chemotherapy including 5-fluoruacil or its prodrugs and derivates, Oxaliplatin and Irinotecan or a combination of the aforementioned. Previous biologicals/antibodies/small molecules including anti-EGFR and anti-VEGF directed therapies are allowed but not mandatory to meet eligibility. Trifluridin/Tipiracil (TAS102) or Regorafenib are allowed but not mandatory as previous therapies for PART I and PART II of the trial. All patients must have a documented Irinotecan-free interval of at least 6 months to be eligible for the study. The study consists of two parts: PART I: a single arm run in phase, treating 20 patients with Sacituzumab Govitecan (SG) PART II: a 1:1 randomized open label phase, comparing 30 patients treated with SG vs. 30 patients treated according to Physicians Choice (PhC). Crossover to the experimental arm (SG) is allowed in case of progression in the standard arm (PhC). PART II will only be started if significant clinical efficacy and activity is observed in PART I.

NCT ID: NCT06242067 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Second-line Treatment of Metastatic Colorectal Cancer

BEV-TASIRI
Start date: April 23, 2023
Phase: Phase 2
Study type: Interventional

The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of recurrence.

NCT ID: NCT06231017 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Start date: January 19, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab plus cetuximab and chemotherapy for patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer.

NCT ID: NCT06228326 Recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Start date: February 2024
Phase: Phase 1
Study type: Interventional

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced solid tumor malignancies affecting the lungs who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The study will include a dose escalation portion for single agent KB707 using a standard 3+3 design followed by an expansion portion to further evaluate single agent KB707 at a dose determined by preliminary data in the dose escalation phase. Subjects in both the dose escalation and dose expansion cohorts will receive KB707 via nebulization weekly for three weeks, then every three weeks for up to two years until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.